Vericel
Michael Halpin is the current Chief Operating Officer at Vericel Corporation since April 2017. Prior to that, Michael held various positions at Sanofi Genzyme, including Senior Vice President Quality and Regulatory Affairs. With a background in biomedical and medical engineering from the University of Virginia, Michael has extensive experience in quality and regulatory affairs in the healthcare industry, including roles at MediSense, Abbott Laboratories Medisense Products, and Abiomed.
This person is not in any offices
Vericel
Vericel (NASDAQ:VCEL) develops, manufactures and markets autologous expanded cell therapies for the treatment of patients with serious diseases and conditions